vs
Side-by-side financial comparison of TrueCar, Inc. (TRUE) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
Viridian Therapeutics, Inc.\DE is the larger business by last-quarter revenue ($70.6M vs $43.2M, roughly 1.6× TrueCar, Inc.). TrueCar, Inc. runs the higher net margin — 11.6% vs -49.0%, a 60.6% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs -7.2%). TrueCar, Inc. produced more free cash flow last quarter ($11.2M vs $-84.7M).
TrueCar, Inc. is an American car retailing website company headquartered in Santa Monica, California. It also maintains a sales office in Austin, Texas.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
TRUE vs VRDN — Head-to-Head
Income Statement — Q3 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $43.2M | $70.6M |
| Net Profit | $5.0M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | -17.0% | -56.7% |
| Net Margin | 11.6% | -49.0% |
| Revenue YoY | -7.2% | 81958.1% |
| Net Profit YoY | 185.7% | 54.9% |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $43.2M | $70.6M | ||
| Q2 25 | $47.0M | — | ||
| Q1 25 | $44.8M | — | ||
| Q4 24 | $46.2M | — | ||
| Q3 24 | $46.5M | — | ||
| Q2 24 | $41.8M | — | ||
| Q1 24 | $41.1M | — | ||
| Q4 23 | $41.3M | — |
| Q3 25 | $5.0M | $-34.6M | ||
| Q2 25 | $-7.6M | — | ||
| Q1 25 | $-10.1M | — | ||
| Q4 24 | $-5.8M | — | ||
| Q3 24 | $-5.8M | — | ||
| Q2 24 | $-13.5M | — | ||
| Q1 24 | $-5.8M | — | ||
| Q4 23 | $-1.9M | — |
| Q3 25 | -17.0% | -56.7% | ||
| Q2 25 | -18.3% | — | ||
| Q1 25 | -25.0% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | -15.9% | — | ||
| Q2 24 | -36.3% | — | ||
| Q1 24 | -18.2% | — | ||
| Q4 23 | -8.7% | — |
| Q3 25 | 11.6% | -49.0% | ||
| Q2 25 | -16.2% | — | ||
| Q1 25 | -22.6% | — | ||
| Q4 24 | -12.7% | — | ||
| Q3 24 | -12.5% | — | ||
| Q2 24 | -32.3% | — | ||
| Q1 24 | -14.2% | — | ||
| Q4 23 | -4.6% | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $103.2M | $490.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $114.2M | $503.0M |
| Total Assets | $148.7M | $577.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $103.2M | $490.9M | ||
| Q2 25 | $92.5M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $111.8M | — | ||
| Q3 24 | $114.5M | — | ||
| Q2 24 | $128.0M | — | ||
| Q1 24 | $133.7M | — | ||
| Q4 23 | $137.0M | — |
| Q3 25 | $114.2M | $503.0M | ||
| Q2 25 | $106.4M | — | ||
| Q1 25 | $111.1M | — | ||
| Q4 24 | $118.1M | — | ||
| Q3 24 | $128.0M | — | ||
| Q2 24 | $143.9M | — | ||
| Q1 24 | $156.0M | — | ||
| Q4 23 | $160.2M | — |
| Q3 25 | $148.7M | $577.1M | ||
| Q2 25 | $139.8M | — | ||
| Q1 25 | $145.0M | — | ||
| Q4 24 | $159.7M | — | ||
| Q3 24 | $167.5M | — | ||
| Q2 24 | $183.0M | — | ||
| Q1 24 | $193.5M | — | ||
| Q4 23 | $204.3M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.7M | $-84.6M |
| Free Cash FlowOCF − Capex | $11.2M | $-84.7M |
| FCF MarginFCF / Revenue | 25.9% | -120.1% |
| Capex IntensityCapex / Revenue | 3.5% | 0.2% |
| Cash ConversionOCF / Net Profit | 2.55× | — |
| TTM Free Cash FlowTrailing 4 quarters | $-19.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $12.7M | $-84.6M | ||
| Q2 25 | $-2.8M | — | ||
| Q1 25 | $-7.9M | — | ||
| Q4 24 | $5.9M | — | ||
| Q3 24 | $1.8M | — | ||
| Q2 24 | $-2.0M | — | ||
| Q1 24 | $2.0M | — | ||
| Q4 23 | $-5.8M | — |
| Q3 25 | $11.2M | $-84.7M | ||
| Q2 25 | $-4.8M | — | ||
| Q1 25 | $-10.6M | — | ||
| Q4 24 | $4.1M | — | ||
| Q3 24 | $-170.0K | — | ||
| Q2 24 | $-3.6M | — | ||
| Q1 24 | $-511.0K | — | ||
| Q4 23 | $-8.1M | — |
| Q3 25 | 25.9% | -120.1% | ||
| Q2 25 | -10.2% | — | ||
| Q1 25 | -23.6% | — | ||
| Q4 24 | 9.0% | — | ||
| Q3 24 | -0.4% | — | ||
| Q2 24 | -8.7% | — | ||
| Q1 24 | -1.2% | — | ||
| Q4 23 | -19.7% | — |
| Q3 25 | 3.5% | 0.2% | ||
| Q2 25 | 4.2% | — | ||
| Q1 25 | 6.0% | — | ||
| Q4 24 | 3.7% | — | ||
| Q3 24 | 4.2% | — | ||
| Q2 24 | 3.9% | — | ||
| Q1 24 | 6.2% | — | ||
| Q4 23 | 5.7% | — |
| Q3 25 | 2.55× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
